Condition: Urothelial Cancer · Urinary Bladder Neoplasms · Sponsor: Astellas Pharma Global Development, Inc.
This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together as a bladder preservation approach to treat patients with muscle invasive bladder cancer. The study will compare these drugs to concurrent chemoradiotherapy that is usually used to treat this cancer (standard of care). The study will enroll patients with muscle-invasive bladder cancer (MIBC) who have cancer that has not spread outside the bladder.
This description comes directly from the study's public registry record.
Pfizer CT.gov Call Center · 1-800-718-1021 · ClinicalTrials.gov_Inquiries@pfizer.com
Always discuss trial participation with your own doctor first.
| Samsun Clinic - Ridley-Tree Cancer Center | Santa Barbara, California, United States | Recruiting |
| Medical Oncology Hematology Consultants | Newark, Delaware, United States | Recruiting |
| Illinois Cancer Specialists | Niles, Illinois, United States | Recruiting |
| Fort Wayne Medical Oncology and Hematology | Fort Wayne, Indiana, United States | Recruiting |
| Missouri Cancer Associates | Columbia, Missouri, United States | Recruiting |
| Williamette Valley Cancer Institute and Research Center | Eugene, Oregon, United States | Recruiting |
| Compass Oncology - West | Tigard, Oregon, United States | Recruiting |
| SCRI Oncology Partners | Nashville, Tennessee, United States | Recruiting |
| Texas Oncology | Austin, Texas, United States | Recruiting |
| Texas Oncology - Northeast Texas | Tyler, Texas, United States | Recruiting |
| Virginia Oncology Associates | Norfolk, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07566156